Odonate Therapeutics Inc (ODT) Fundamental Analysis & Valuation

NASDAQ:ODT

Current stock price

1.12
-0.05 (-4.27%)
At close:
1.11
-0.01 (-0.89%)
After Hours:

This ODT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ODT Profitability Analysis

1.1 Basic Checks

  • In the past year ODT has reported negative net income.
ODT Yearly Net Income VS EBIT VS OCF VS FCFODT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -20M -40M -60M -80M -100M

1.2 Ratios

Industry RankSector Rank
ROA -96.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ODT Yearly ROA, ROE, ROICODT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 -20 -40 -60 -80 -100

1.3 Margins

  • ODT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ODT Yearly Profit, Operating, Gross MarginsODT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ODT Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ODT has been increased compared to 1 year ago.
  • ODT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ODT Yearly Shares OutstandingODT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 10M 20M 30M
ODT Yearly Total Debt VS Total AssetsODT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -7.42, we must say that ODT is in the distress zone and has some risk of bankruptcy.
  • ODT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.42
ROIC/WACCN/A
WACCN/A
ODT Yearly LT Debt VS Equity VS FCFODT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 100M -100M

2.3 Liquidity

  • ODT has a Current Ratio of 3.29. This indicates that ODT is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 3.29 indicates that ODT has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.29
ODT Yearly Current Assets VS Current LiabilitesODT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ODT Growth Analysis

3.1 Past

  • ODT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.46%, which is quite impressive.
EPS 1Y (TTM)31.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y54.53%
EPS Next 2Y40.68%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ODT Yearly EPS VS EstimatesODT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. ODT Valuation Analysis

4.1 Price/Earnings Ratio

  • ODT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ODT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ODT Price Earnings VS Forward Price EarningsODT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.58
ODT Per share dataODT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ODT's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.68%
EPS Next 3Y25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ODT Dividend Analysis

5.1 Amount

  • ODT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ODT Fundamentals: All Metrics, Ratios and Statistics

Odonate Therapeutics Inc

NASDAQ:ODT (1/14/2022, 8:44:12 PM)

After market: 1.11 -0.01 (-0.89%)

1.12

-0.05 (-4.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)03-01
Inst Owners0.06%
Inst Owner Change0%
Ins Owners20.59%
Ins Owner Change0%
Market Cap43.11M
Revenue(TTM)N/A
Net Income(TTM)-102.07M
Analysts46.67
Price Target4.08 (264.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB N/A
EV/EBITDA 0.58
EPS(TTM)-2.68
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.85
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -96.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.29
Altman-Z -7.42
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.22%
EPS Next Y54.53%
EPS Next 2Y40.68%
EPS Next 3Y25.99%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Odonate Therapeutics Inc / ODT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Odonate Therapeutics Inc?

ChartMill assigns a fundamental rating of 2 / 10 to ODT.


What is the valuation status for ODT stock?

ChartMill assigns a valuation rating of 3 / 10 to Odonate Therapeutics Inc (ODT). This can be considered as Overvalued.


How profitable is Odonate Therapeutics Inc (ODT) stock?

Odonate Therapeutics Inc (ODT) has a profitability rating of 1 / 10.


Can you provide the financial health for ODT stock?

The financial health rating of Odonate Therapeutics Inc (ODT) is 3 / 10.